close

Enter

Log in using OpenID

Animal Depression Medication Market

embed
Emotions may be described as subjective, conscious experiences characterized by psychophysiological expressions, mental states, and biological reactions.
Animal Depression Medication Market Major Players
Analysis with growth By 2026
Animal Depression Medication Market Overview
Emotions may be described as subjective, conscious experiences characterized by
psychophysiological expressions, mental states, and biological reactions. Several tests such as
cognitive bias test and leaned helplessness models have been developed to understand feelings
of optimism and pessimism in animals. Cognitive biases have been shown in wide range of
species, including rats, dogs, cats, sheep, and chicks.
Get Sample Copy At: https://www.coherentmarketinsights.com/insight/request-sample/90
Depression in animals can be due to change in routine or change in emotions. Some animals
can get depressed when left alone for long hours. Animals can also suffer from depression due
to chemical imbalance, which can be treated with medication. Different animals have different
reactions to depression. This can be spotted by looking out for ordinary behavior i.e. when an
active animal becomes listless and a calm animal seems anxious. Animals in the zoo are
subjected to live in artificial, stressful, and boring conditions. Detached from their natural
habitats and social structures, they are kept in small, restrictive environments that deprive them
of mental and physical stimulation and in turn causes depression.
Treatment alternatives for animal depression to boost growth of the animal depression
medication market
Treatment of animal depression varies according to cause of condition. Blood tests, x-rays, and
a physical examination by a veterinarian can help with diagnosis. If the animal has chemical
imbalance, then the veterinarian may prescribe anti-depressants or anxiety medication.
Paroxetine is an antidepressant used to treat major depressive disorders, social anxiety disorder,
and panic disorder. The current standard of treatment of depression involves use of selective
serotonin reuptake inhibitors (SSRIs). Depression can be triggered due to lack of serotonin, and
SSRIs essentially maintain higher levels of serotonin in the brain to address the issue. It can
take up to two months for a drug to be effective in treating depression. Most dogs suffering
from such disorders can make a full recovery in six to twelve months after being administered
SSRIs. The U.S. Food and Drug Administration has approved only one antidepressant,
Clomicalm (clomipramine) for treatment of anxiety in dogs, which would fuel growth of the
animal depression medication market.
Increasing pet adoption and growing pet humanization trend driving growth of animal
depression medication market in Asia Pacific and Latin America
North America is a major region for animal depression medication market. As per 2015 Pet
Secure estimates, the U.S. accounted for the highest dog population of 69,929,000. Animal
depression medication market in Asia is growing on account of increasing awareness among the
populace regarding animal illness, increasing number of pets, and improving veterinary medical
facilities. According to the Pet Asia Fair in 2016, pet adoption in Asia Pacific and Latin
America regions is increasing rapidly resulting in increase in demand for nutritional and
medicinal products in order to address their growing health concerns.
Increasing spending on animal care to boost growth of the animal depression medication market
Increasing number of pet animals is a major factor fueling growth of the animal depression
medication market. According to 2016 estimates released by Pet Secure, over half of the
population in the U.S. owns a cat or a dog. This is mainly attributed to increasing consumer
awareness regarding the various social, emotional, and physical benefits associated with pet
ownership. Therefore, with increasing number of pets, there is an increasing spending on pet
animals, further fueled by pet humanization trend. According to 2016 estimates of Pet Secure,
the U.S. population spends over US$ 50 billion per annum on their pets. This is projected to
fuel growth of the animal depression medications market in the near future. Other factors
include awareness about animal illness, better medical facilities, use of latest technology in
diagnosis, and increased spending capabilities on animal treatment.
Browse Complete Report For More Information @
https://www.coherentmarketinsights.com/ongoing-insight/animal-depression-medication-market-90
Key players involved in the animal depression medication market
Major players in the global animal depression medication market include Torrent
Pharmaceuticals Limited, Elite Pharma Private Limited, Biomax Laboratories, Intas
Pharmaceuticals Limited, Cipla Limited, and Eli Lilly and Company. These companies provide
drugs that are used to treat depression in animals.
Key Developments
Increasing product approval and launch of animal depression drugs is expected to boost the
market growth. For instance, in August 2019, Lupin Limited launched Fluoxetine Tablets USP,
10 mg and 20 mg, a generic version to Eli Lilly and Company’s Proxac tablets.
Similarly, in February 2019, Lupin Limited announced the launch of Clomipramine
Hydrochloride Capsules USP, a generic version of SpecGx LLC’s Anafranil Capsule, having
received an approval from the U.S. Food and Drug Administration (FDA) earlier.
Research related to anti-depression drugs is also expected to boost the market. For instance, in
July 2019, according to a research published in Lancet Psychiatry, interpretation of depression
scale scores may indicate inaccurately that selective serotonin reuptake inhibitors (SSRIs) are not
as effective for nonsevere depression.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
Author
Alex Huge
Alex Huge415   documents Email
Document
Category
Health and Medicine
Views
1
File Size
109 KB
Tags
market, animal depression medication market
1/--pages
Report inappropriate content